Silvia retweetet

FUZION trial of guselkumab for perianal Crohn’s disease—MRIs obtained at baseline, midpoint and end—approx 1/3 bio-naive—both doses equally effective at week 24. Great to have another well studied option for this troubling complication #DDW2026 @DDWMeeting




English























